• MJHLS Brand Logo

© 2025 MJH Life Sciences™ and The Center for Biosimilars - Biosimilars, Health Economics & Insights. All rights reserved.

Oncology

Top 5 Most-Read Oncology Articles of 2024

December 24th 2024

By Skylar Jeremias

Article

The top 5 oncology biosimilar articles in 2024 cover Duke's recommendations for cell and gene therapy biosimilars, FDA approval of Shanghai Henlius Biotech's trastuzumab biosimilar, Boehringer Ingelheim layoffs, the safety of rituximab biosimilar CT-P10, and more.

Study Shows Biosimilarity of Bevacizumab Biosimilar in CRC

December 17th 2024

By Skylar Jeremias

Article

A recent study showed similar safety and efficacy of a bevacizumab biosimilar compared with the reference product (Avastin) in patients with metastatic colorectal cancer (CRC).

Review Confirms Clinical Safety of Sandoz Denosumab Biosimilar vs Originator

December 11th 2024

By Skylar Jeremias

Article

Sandoz's biosimilar denosumab (Jubbonti/Wyost) has demonstrated analytical, pharmacokinetic, pharmacodynamic, and clinical equivalence to reference denosumab (Prolia/Xgeva), supporting its approval and extrapolation to all approved indications.

Eye on Pharma: Golimumab Biosimilar Update; Korea Approves Denosumab; Xbrane, Intas Collaboration

December 10th 2024

By Skylar Jeremias

Article

Alvotech and Advanz Pharma have submitted a European marketing application for their golimumab biosimilar to treat inflammatory diseases, while Celltrion secured Korean approval for denosumab biosimilars, and Intas Pharmaceuticals partnered with Xbrane Biopharma on a nivolumab biosimilar.

Pertuzumab Biosimilar Shows Promise in HER2-Positive Breast Cancer Treatment

December 9th 2024

By Skylar Jeremias

Article

The proposed pertuzumab biosimilar QL1209 demonstrated equivalent efficacy and safety to reference pertuzumab (Perjeta) in neoadjuvant treatment of HER2-positive, ER/PR-negative early or locally advanced breast cancer, offering a cost-effective alternative with comparable clinical outcomes.

Switching to Rituximab Biosimilars Is Safe, Effective for Patients With Oncohematological Diseases

December 5th 2024

By Cameron Santoro

Article

Patients with oncohematological diseases switching to rituximab biosimilars experienced similar safety and efficacy, highlighting biosimilars' potential for cost-effective treatment across various medical conditions.

Retrospective Study Shows Bevacizumab Biosimilar Efficacy in NSCLC

November 27th 2024

By Skylar Jeremias

Article

Bevacizumab biosimilars have the potential to expand access and reduce costs without compromising patient outcomes in advanced non–small cell lung cancer (NSCLC)

Denosumab Biosimilars Earn Positive CHMP Opinion for Bone Loss and Giant Cell Tumor of Bone

November 26th 2024

By Ashling Wahner

Article

The European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for the denosumab biosimilars SB16 for all indications referencing Prolia and Xgeva.

Achieving PFS in Advanced Gastric Cancer With HLX02 Biosimilar, Chemotherapy

November 23rd 2024

By Deana Ferreri, PhD

Article

In a phase 2 study, the addition of HLX22, an anti-HER2 antibody, to HLX02 biosimilar and XELOX (oxaliplatin and capecitabine) chemotherapy extended progression-free survival (PFS) in untreated HER2-positive advanced gastric cancer patients.

Financial Incentives Boost Oncology Biosimilar Adoption, but Costs Remain Unchanged

November 20th 2024

By Skylar Jeremias

Article

Although financial incentives introduced by Japan's 2022 health policy did not result in a reduction in overall drug costs, biosimilar use in oncology significantly increased.